Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 6/20 | 0.49 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.49 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631546 | 0.91 | L3MBTL1 (0.48) | POLBL3MBTL1LMNAKMT2A | |
| SCHEMBL5840913 | 0.86 | POLB (0.49) | SSTR5SSTR3SSTR2SSTR1SSTR4 | |
| SCHEMBL5840906 | 0.86 | POLB (0.49) | SSTR5SSTR3SSTR2SSTR1SSTR4 | |
| SCHEMBL23631561 | 0.84 | POLB (0.66) | SSTR5SSTR3SSTR2SSTR1SSTR4 | |
| SCHEMBL13491599 | 0.83 | POLB (0.52) | SSTR5SSTR3SSTR2SSTR1SSTR4 | |
| SCHEMBL7583524 | 0.83 | POLB (0.52) | SSTR5SSTR3SSTR2SSTR1SSTR4 | |
| SCHEMBL23631544 | 0.82 | POLB (0.52) | SSTR5SSTR3SSTR2SSTR1SSTR4 | |
| SCHEMBL23631539 | 0.81 | POLB (0.55) | POLBL3MBTL1LMNAKMT2A | |
| SCHEMBL23631545 | 0.81 | POLB (0.55) | SSTR5SSTR3SSTR2SSTR1SSTR4 | |
| SCHEMBL23631559 | 0.80 | POLB (0.50) | SSTR5SSTR3SSTR2SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365212-B2 | Fluorinated N-acetyl glucosamine analogs and xylose derivatives | UTI LIMITED PARTNERSHIP (CA) | 2022-06-21 | — | — | US | disclosed |
| US-20210214384-A1 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | UTI LIMITED PARTNERSHIP (CA) | 2021-07-15 | — | — | US | disclosed |
| WO-2019227228-A1 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | UTI LIMITED PARTNERSHIP (CA) | 2019-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365212-B2 | Fluorinated N-acetyl glucosamine analogs and xylose derivatives | FUT6, FUT5, B3GNT2 | SSTR5 878/4885SSTR3 833/4885SSTR2 1291/4885 |
| US-20210214384-A1 | FLUORINATED N-ACETYL GLUCOSAMINE ANALOGS AND XYLOSE DERIVATIVES | FUT6, FUT5, B3GNT2 | SSTR5 878/4885SSTR3 833/4885SSTR2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.